Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

Inclusion Criteria: Male or female Histologically or cytologically 3b or 4 (metastatic) non-small cell lung cancer. Patients must meet any subcriteria as detailed in the protocol. Age greater than or equal to 18 years old ECOG performance status of 0 to 1 Prior diagnosis of brain metastases from NSCLC eligible provided that the brain metastases have been adequately treated, patient is neurologically stable and no new or progressive brain metastases identified. Meets protocol requirements for specified laboratory values Written informed consent Appropriate use of effective contraception if of childbearing potential Prior basal cell carcinoma or carcinoma in-situ of the cervix are eligible provided they have been treated with no evidence of disease Exclusion Criteria: Prior chemotherapy for any stage of NSCLC Prior surgery or radiation therapy within the last 2 weeks or incomplete recovery from prior procedures or therapy Concurrent treatment or treatment within the last 2 years for any other malignancy Grade 2 or greater nausea or Grade 1 or greater vomiting (despite antiemetic medication) Medical conditions that would interfere with taking oral medications Patients with bone metastases as the only site of disease Pregnant or nursing women Known HIV positivity or AIDS-related illness Patients with significant QTc prolongation at baseline